Rx Equioxx Paste 6.93 gm

Rx Equioxx Paste 6.93 gm

Product #: 07982
Availability: 20 IN STOCK
6.93g Paste
Price: $4.95

Equioxx Oral Paste Horse Arthritis Treatment is an equine arthritis treatment proven to relieve pain and inflammation associated with equine osteoarthritis. Equioxx, a brand of firocoxib, is a veterinary prescription-only non-steroidal anti-inflammatory drug (NSAID) for horse arthritis available is an easily administered well tolerated oral paste. Each dose of Equioxx delivers 24 hours of targeted pain relief per dose and has an excellent safety profile on gastrointestinal, hepatic and renal functions. One syringe of equioxx treats a 1250 lb. horse. Each weight marking on the equioxx syringe treats 250 lbs.
Equioxx Oral Paste Horse Arthritis Treatment requires a prescription.


EQUIOXX (firocoxib) belongs to the coxib class of non-narcotic, non-steroidal anti-inflammatory drugs (NSAID). Firocoxib is a white crystalline compound described chemically as 3-(cyclopropylmethoxy)-4-(4-(methylsulfonyl)phenyl-5, 5-dimethylfuranone. The empirical formula is C17H20O5S, and the molecular weight is 336.4. The structural formula is shown below:

EQUIOXX Injection is a colorless to pale yellow solution. Each mL of EQUIOXX Injection for Horses contains 20 mg of firocoxib as a free base, 550 mg of polyethylene glycol (PEG 400) and 600 mg of glycerol formal.

EQUIOXX Injection Indications

EQUIOXX Injection is administered for up to 5 days for the control of pain and inflammation associated with osteoarthritis in horses.
EQUIOXX Injection Dosage And Administration

Always provide the Client Information Sheet with the prescription. The recommended dosage of EQUIOXX Injection for intravenous administration in horses is 0.04 mg/lb (0.09 mg/kg) of body weight once daily for up to 5 days. If further treatment is needed, EQUIOXX (firocoxib) Oral Paste for horses can be used at a dosage of 0.045 mg/lb (0.1 mg/kg) body weight for up to an additional 9 days of treatment. The overall duration of treatment with EQUIOXX Injection and EQUIOXX Oral Paste will be dependent on the response observed, but should not exceed 14 days. See EQUIOXX Oral Paste for horses package insert for dosage and administration. EQUIOXX Injection is a non-aqueous solution, and therefore should not be added to an aqueous solution (such as intravenous infusion lines).

Horses with hypersensitivity to firocoxib should not receive EQUIOXX Injection.

For intravenous use in horses only. Do not use in horses intended for human consumption.
Human Warnings

Not for use in humans. Keep this and all medications out of the reach of children. Consult a physician in case of accidental human exposure.
Animal Safety

Clients should be advised to observe for signs of potential drug toxicity and be given a Client Information Sheet with each prescription.
For technical assistance or to report suspected adverse events call 1-877-217-3543.


Horses should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests should be conducted to establish hematological and serum biochemical baseline data before and periodically during administration of any NSAID. Clients should be advised to observe for signs of potential drug toxicity and be given a Client Information Sheet with each prescription. See Information for Owner or Person Treating Horse section of this package insert.
Treatment with EQUIOXX should be terminated if signs such as inappetance, colic, abnormal feces, or lethargy are observed.

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Horses that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for adverse events are those that are dehydrated, on diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached or avoided. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since many NSAIDs possess the potential to produce gastrointestinal ulcerations and/or gastrointestinal perforation, concomitant use of EQUIOXX Injection with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided.

The concomitant use of protein bound drugs with EQUIOXX Injection for horses has not been studied in horses. The influence of concomitant drugs that may inhibit the metabolism of firocoxib Injection has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.

The safe use of EQUIOXX Injection for horses has not been evaluated in horses less than one year of age, horses used for breeding, or in pregnant or lactating mares.

Consider appropriate washout times when switching from one NSAID to another NSAID or corticosteroid.

Adverse Reactions

The effectiveness of EQUIOXX Injection was established in a biocomparability study demonstrating that EQUIOXX Oral Paste is bioequivalent to EQUIOXX Injection. Thus, additional field studies were not performed to support the effectiveness of EQUIOXX Injection.
In controlled field studies, 127 horses (ages 3 to 37 years) were evaluated for safety when given EQUIOXX® (firocoxib) Oral Paste for Horses at a dose of 0.045 mg/lb (0.1 mg/kg) orally once daily for up to 14 days. The following adverse reactions were observed. Horses may have experienced more than one of the observed adverse reactions during the study.